SCHEMBL2163097

SCHEMBL2163097

CCC(Cl)Oc1cc2nnnc(Nc3ccc(Cl)c(Cl)c3)c2cc1OC

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.48
EPHA2 P29317 18/20 0.48
EPHB4 P54760 16/20 0.48
ERBB2 P04626 7/20 0.48
EGFR P00533 2/20 0.48
FLT1 P17948 4/20 0.47
AURKA O14965 1/20 0.45
INSR P06213 1/20 0.45
FBP1 P09467 1/20 0.45
PDGFRB P09619 1/20 0.45
FLT4 P35916 1/20 0.45
CLK1 P49759 1/20 0.45
TEK Q02763 1/20 0.45
AURKB Q96GD4 1/20 0.45
RET P07949 1/20 0.45
KIF5B P33176 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2164226 0.91 EGFR (0.58) KDREPHB4ERBB2EGFRAURKA
SCHEMBL2163493 0.90 KDR (0.54) KDREPHB4ERBB2EGFRFLT1
SCHEMBL2163565 0.88 SLC2A1 (0.50) KDRERBB2EGFRFLT1RET
SCHEMBL2165591 0.87 EGFR (0.56) KDREPHA2ERBB2EGFRFBP1
SCHEMBL2164524 0.87 EGFR (0.53) KDREPHB4ERBB2EGFRFLT1
SCHEMBL2163601 0.86 EGFR (0.42) KDREPHA2EPHB4ERBB2EGFR
SCHEMBL2163645 0.86 EGFR (0.51) KDRERBB2EGFRFLT1AURKA
SCHEMBL2163808 0.85 EPHA2 (0.57) KDREPHA2EPHB4ERBB2EGFR
SCHEMBL2164421 0.84 EGFR (0.44) KDREPHA2EPHB4ERBB2EGFR
SCHEMBL2163631 0.84 EGFR (0.55) KDRERBB2EGFRFBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US claimed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US claimed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP claimed
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US disclosed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US disclosed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF KDR, FLT1, FLT4 KDR 1/4885EPHA2 625/4885EPHB4 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.